Advertisement
Canada markets close in 4 hours 8 minutes
  • S&P/TSX

    21,838.51
    +130.07 (+0.60%)
     
  • S&P 500

    4,992.96
    -18.16 (-0.36%)
     
  • DOW

    37,951.05
    +175.67 (+0.47%)
     
  • CAD/USD

    0.7275
    +0.0012 (+0.16%)
     
  • CRUDE OIL

    82.91
    +0.18 (+0.22%)
     
  • Bitcoin CAD

    88,863.41
    +1,339.79 (+1.53%)
     
  • CMC Crypto 200

    1,385.55
    +72.93 (+5.89%)
     
  • GOLD FUTURES

    2,404.60
    +6.60 (+0.28%)
     
  • RUSSELL 2000

    1,946.93
    +3.97 (+0.20%)
     
  • 10-Yr Bond

    4.6060
    -0.0410 (-0.88%)
     
  • NASDAQ

    15,429.35
    -172.15 (-1.10%)
     
  • VOLATILITY

    18.69
    +0.69 (+3.83%)
     
  • FTSE

    7,895.85
    +18.80 (+0.24%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • CAD/EUR

    0.6823
    +0.0002 (+0.03%)
     

What Analysts Recommend for Bluebird Bio Stock

What Analysts Recommend for Bluebird Bio Stock

As previously discussed, analysts expect Bluebird Bio (BLUE) to post revenue of $9.6 million, a net adjusted loss of ~$123.5 million, and EPS of -$2.35 in the second quarter. Of the 21 analysts tracking Bluebird Bio, five recommend “strong buy,” nine recommend “buy,” six recommend “hold,” and one recommends “sell.”